Homegrown pharma major Dr Reddy’s Laboratories Ltd on Friday said it has entered into a settlement agreement with Indivior Inc and Aquestive Therapeutics as a result of which it will receive payments totalling $72 million (over Rs 560 crore) by March 31, 2024.

The said agreement resolves all claims between the parties relating to the company’s generic buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, Dr Reddy’s Laboratories said in a regulatory filing.

The settlement also covers Indivior’s and Aquestive’s patent infringement allegations and the company’s antitrust counterclaims, it added. Buprenorphine and naloxone sublingual film medication is used to treat opioid dependence or addiction.

“Pursuant to the agreement, the company will receive payments totalling $72 million by March 31, 2024,” Dr Reddy’s said adding, as part of the settlement, the underlying litigation will also be dismissed.